Sling Therapeutics announced a $123 million Series C financing.
- Amount
- $123M
- Stage
- Series C
- Announced
- 16 September 2026
- Lead
- Forbion
- Use of funds
- Advance Phase 3 development of linsitinib, an oral small molecule IGF-1R inhibitor, for thyroid eye disease.
- Checked
- Amount and date checked against the press source